GlassScriptPhysician profile
Frank Scafuri
NPI 1588641849
$3,432.12
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,653 · 2020: $717 · 2021: $33.75 · 2022: $28.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $504.36 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $381.26 | 2019-2020 | |
| Gilead Sciences, INC. | $255.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $222.01 | 2019-2020 | |
| Allergan, INC. | $205.10 | 2019-2020 | |
| Novo Nordisk INC | $162.16 | 2019-2020 | |
| Philips North America LLC | $141.84 | 2019-2020 | |
| Amarin Pharma, INC. | $137.21 | 2019-2020 | |
| Viiv Healthcare Company | $125.19 | 2019 | |
| Amgen INC. | $116.52 | 2019-2020 | |
| Lilly USA, LLC | $107.67 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $78.44 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $75.40 | 2019-2020 | |
| Insmed, INC. | $66.09 | 2019 | |
| Melinta Therapeutics, LLC | $50.01 | 2019 | |
| Amneal Pharmaceuticals LLC | $45.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.87 | 2019 | |
| Scilex Pharmaceuticals INC. | $38.98 | 2019-2020 | |
| Genentech USA, INC. | $35.79 | 2019 | |
| Eisai INC. | $31.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.51 | 2019 | |
| Abbvie INC. | $30.05 | 2019-2022 | |
| Sanofi Pasteur INC. | $28.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $28.04 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $27.24 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.67 | 2019-2020 | |
| Optinose US, INC. | $23.44 | 2019 | |
| Phadia US INC. | $19.05 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $18.83 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.00 | 2019 | |
| Janssen Biotech, INC. | $16.52 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.66 | 2019 | |
| Currax Pharmaceuticals LLC | $14.43 | 2020 | |
| Lupin INC. | $13.64 | 2019 | |
| Mylan Institutional INC. | $12.82 | 2019 | |
| Napo Pharmaceuticals INC | $12.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Scafuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.